Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lartruvo
Pharma
Telix buys Lilly's failed cancer drug Lartruvo for $5 million
Eli Lilly has licensed certain Lartruvo rights to Australian biotech Telix for a mere $5 million.
Kevin Dunleavy
Apr 11, 2022 11:01am
Lilly eyes current patients amid Lartruvo's global retreat
Apr 25, 2019 11:50am
Lilly chief David Ricks picks up 9% raise to $17.2M
Mar 13, 2019 11:16am
Lartruvo failure, Loxo buy dent Lilly’s 2019 hopes
Feb 6, 2019 11:45am
Lilly's Lartruvo hits a wall as FDA warns against new starts
Jan 25, 2019 10:20am
Europe bars new patients from starting Lilly's Lartruvo
Jan 23, 2019 10:13am
